Fierce Virtual Series: JPM Week 2021 has ended
avatar for Heejin Kim, Ph.D.

Heejin Kim, Ph.D.

Prazer Therapeutics
Business Development Director I U.S. Patent Agent
Seoul, South Korea

Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational molecular drug design technology and the next-generation targeted protein degradation (TPD) platform called SPiDEM.

Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).

We are looking for collaboration opportunities in R&D, clinical development and commercialization. I would be very interested in learning more about your company and look forward to discussing further. For more information about our company, please visit our website www.prazertx.com. If you have any question or suggestion, please feel free to contact me at kimhj@prazertx.com. Thank you!
  • Timezone
  • Filter By Date Fierce Virtual Series: JPM Week 2021 Jan 11 -13, 2021
  • Filter By Type
  • Interviews
  • Keynote
  • Networking
  • Panel Discussions
  • Presentations